Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Allergy Clin Immunol. 2006 Jan;117(1):34-9.

"Black box" 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk.

Author information

  • 1US Food and Drug Administration, Center for Drug Evaluation and Research, Office of Counter-Terrorism and Pediatric Drug Development, Silver Spring, MD 20993, USA. murphys@cder.fda.gov

Abstract

A prominently displayed boxed warning, the so-called "black box," is added to the labeling of drugs or drug products by the Food and Drug Administration when serious adverse reactions or special problems occur, particularly those that may lead to death or serious injury. Healthcare providers are often not knowledgeable about the origin, meaning, and implications of these "black box" warnings. In this review, our goal is to provide insight into how the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk. We discuss drug labeling, the emphasis on safety throughout the drug approval process, legislative initiatives for safe use of drugs in children, and postmarketing safety surveillance. In addition, we encourage health care providers to report drug reactions to the Food and Drug Administration's MedWatch program. A discussion of new Food and Drug Administration initiatives to improve drug safety processes and methods to serve the public better are highlighted.

Comment in

PMID:
16387581
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk